Trials / Recruiting
RecruitingNCT06493019
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- Dustin Deming · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Chemoradiation Pembrolizumab 200mg IV |
| DRUG | Paclitaxel | Paclitaxel 50 mg/m\^2 IV |
| DRUG | Carboplatin | Carboplatin AUC 2 IV |
| RADIATION | Radiation | Delivered as per institutional standards |
| DRUG | Pembrolizumab | Maintenance Pembrolizumab 400mg IV |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2027-04-15
- Completion
- 2029-04-14
- First posted
- 2024-07-09
- Last updated
- 2026-03-23
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06493019. Inclusion in this directory is not an endorsement.